Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being
Natasha L. Mason, Elisabeth Mischler, Malin V. Uthaug, et al.
Journal of Psychoactive Drugs (2019) Vol. 51, Iss. 2, pp. 123-134
Open Access | Times Cited: 150

Showing 1-25 of 150 citing articles:

Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
Franz X. Vollenweider, Katrin H. Preller
Nature reviews. Neuroscience (2020) Vol. 21, Iss. 11, pp. 611-624
Closed Access | Times Cited: 415
Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin
Natasha L. Mason, Kim P. C. Kuypers, Felix Müller, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 12, pp. 2003-2011
Open Access | Times Cited: 205
Long-term effects of psychedelic drugs: A systematic review
Jacob S. Aday, Cayla M. Mitzkovitz, Emily K. Bloesch, et al.
Neuroscience & Biobehavioral Reviews (2020) Vol. 113, pp. 179-189
Closed Access | Times Cited: 188
Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics
Cato M. H. de Vos, Natasha L. Mason, Kim P. C. Kuypers
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 176
Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness
Hannes Kettner, Fernando Rosas, Christopher Timmermann, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 152
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
Michiel van Elk, David B. Yaden
Neuroscience & Biobehavioral Reviews (2022) Vol. 140, pp. 104793-104793
Open Access | Times Cited: 113
The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation
James Rucker, Lindsey Marwood, Riikka-Liisa Johanna Ajantaival, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 1, pp. 114-125
Open Access | Times Cited: 80
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder
Adam W. Levin, Rafael Lancelotta, Nathan D. Sepeda, et al.
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0300501-e0300501
Open Access | Times Cited: 24
Spontaneous and deliberate creative cognition during and after psilocybin exposure
Natasha L. Mason, Kim P. C. Kuypers, Johannes T. Reckweg, et al.
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 99
A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats
Malin V. Uthaug, Natasha L. Mason, Stefan W. Toennes, et al.
Psychopharmacology (2021) Vol. 238, Iss. 7, pp. 1899-1910
Open Access | Times Cited: 83
Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review
Kristin Heuschkel, Kim P. C. Kuypers
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 74
Persisting Effects of Ayahuasca on Empathy, Creative Thinking, Decentering, Personality, and Well-Being
Maggie Kiraga, Natasha L. Mason, Malin V. Uthaug, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 64
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution
Devon Stoliker, Gary F. Egan, Karl Friston, et al.
Pharmacological Reviews (2022) Vol. 74, Iss. 4, pp. 876-917
Open Access | Times Cited: 56
Sustained effects of single doses of classical psychedelics in humans
Gitte M. Knudsen
Neuropsychopharmacology (2022) Vol. 48, Iss. 1, pp. 145-150
Open Access | Times Cited: 39
Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study
Natasha L. Mason, Attila Szabó, Kim P. C. Kuypers, et al.
Brain Behavior and Immunity (2023) Vol. 114, pp. 299-310
Open Access | Times Cited: 39
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020
Emma I Kopra, Jason Ferris, Adam Winstock, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 733-748
Open Access | Times Cited: 34
The costs and benefits of psychedelics on cognition and mood
Ceyda Sayalı, Frederick S. Barrett
Neuron (2023) Vol. 111, Iss. 5, pp. 614-630
Open Access | Times Cited: 26
The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics
Ricarda Evens, Marianna E. Schmidt, Tomislav Majić, et al.
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 26
Effects of DMT on mental health outcomes in healthy volunteers
Christopher Timmermann, Richard J. Zeifman, David Erritzøe, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 14
Psychedelic therapy in depression and substance use disorders
Nur Damla Korkmaz, Uğur Çıkrıkçılı, Merve Akan, et al.
European Journal of Neuroscience (2024) Vol. 60, Iss. 2, pp. 4063-4077
Open Access | Times Cited: 10
The Past and Future of Psychedelic Science: An Introduction to This Issue
Richard Doblin, Merete Bruun Christiansen, Lisa Jerome, et al.
Journal of Psychoactive Drugs (2019) Vol. 51, Iss. 2, pp. 93-97
Open Access | Times Cited: 62
The therapeutic potential of microdosing psychedelics in depression
Kim P. C. Kuypers
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 60
Broadening Your Mind to Include Others: The relationship between serotonergic psychedelic experiences and maladaptive narcissism
Valerie van Mulukom, Ruairi Patterson, Michiel van Elk
Psychopharmacology (2020) Vol. 237, Iss. 9, pp. 2725-2737
Open Access | Times Cited: 52
Classical Psychedelics as Therapeutics in Psychiatry – Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders
Lea J. Mertens, Katrin H. Preller
Pharmacopsychiatry (2021) Vol. 54, Iss. 04, pp. 176-190
Closed Access | Times Cited: 52
The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects
Malin V. Uthaug, Alan K. Davis, Trevor Forrest Haas, et al.
Journal of Psychopharmacology (2021) Vol. 36, Iss. 3, pp. 309-320
Open Access | Times Cited: 49
Page 1 - Next Page

Scroll to top